Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

Journal of Thrombosis and Thrombolysis

Volumn 41, Issue 1, 2016, Pages 206-232

  Burnett, Allison E ^a   Mahan, Charles E ^b   Vazquez, Sara R ^c   Oertel, Lynn B ^d   Garcia, David A ^e   Ansell, Jack ^f  

^a UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Antidotes; Bridging anticoagulation; Care transitions; Direct thrombin inhibitors; DOACs; Drug interactions; Factor Xa inhibitors; NOACs

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; DIRECT ORAL ANTICOAGULANT; EDOXABAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BLEEDING; BLEEDING RISK; BODY WEIGHT; BRAIN HEMORRHAGE; BREAST FEEDING; BRIDGE THERAPY; CARE TRANSITION; CHEMOTHERAPY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE CONCEPTS; HIGH RISK POPULATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; MEDICAL HISTORY; MEDICAL LITERATURE; MONOTHERAPY; NEOPLASM; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PATIENT IDENTIFICATION; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PROTHROMBIN TIME; PUBLICATION; RISK; RISK ASSESSMENT; THROMBIN TIME; THROMBOPHILIA; TIME TO TREATMENT; VENOUS THROMBOEMBOLISM; BLOOD; FEMALE; MALE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; VENOUS THROMBOEMBOLISM;

EID: 84954430174     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1310-7     Document Type: Article

References (139)

1. Van der Hulle T, Kooiman J, den Exter PL et al (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12:320–328. doi:10.1111/jth.12485
2. Mantha S, Ansell J (2014) Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis. doi:10.1007/s11239-014-1102-5
3. Schulman S, Kearon C, Kakkar AK et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368:709–718. doi:10.1056/NEJMoa1113697
4. EINSTEIN Investigators, Bauersachs R, Berkowitz SD et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510. doi:10.1056/NEJMoa1007903
5. Agnelli G, Buller HR, Cohen A et al (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368:699–708. doi:10.1056/NEJMoa1207541
6. Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352. doi:10.1056/NEJMoa0906598
7. Schulman S, Kakkar AK, Goldhaber SZ et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764–772. doi:10.1161/CIRCULATIONAHA.113.004450
8. EINSTEIN–PE Investigators, Büller HR, Prins MH et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297. doi:10.1056/NEJMoa1113572
9. Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808. doi:10.1056/NEJMoa1302507
10. Buller FN, Hokusai-VTE Investigators et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415. doi:10.1056/NEJMoa1306638
11. XARELTO-PM-ENG-10JUL2014-172618.pdf. http://www.bayer.ca/files/XARELTO-PM-ENG-10JUL2014-172618.pdf? Accessed 11 Nov 2014
12. Boehringer Ingelheim Canada Ltd (2014) Pradaxa product monograph. http://www.boehringeringelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/PradaxaPMEN.pdf. Accessed 11 Nov 2014
13. Bapat P, Kedar R, Lubetsky A et al (2014) Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol 123:1256–1261. doi:10.1097/AOG.0000000000000277
14. Königsbrügge O, Langer M, Hayde M et al (2014) Oral anticoagulation with rivaroxaban during pregnancy: a case report. Thromb Haemost. doi:10.1160/TH14-04-0393
15. Pfizer Canada Inc Eliquis Product Monograph. http://www.pfizer.ca/en/our_products/products/monograph/313. Accessed 11 Nov 2014
16. Savaysa Edoxaban PI. http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true. Accessed 22 Sept 2015
17. Stangier DJ, Stähle H, Rathgen K, Fuhr R (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:47–59. doi:10.2165/00003088-200847010-00005
18. Frost CE, Nepal S, Barrett Y et al (2009) Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. J Thromb Haemost 7(suppl 2):455
19. Upreti VV, Wang J, Barrett YC et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 76:908–916
20. Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmakokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47(2):218–226
21. Schulman S et al (2014) ASH 56th annual meeting San Francisco, CA Dec 2014, session 332 abstract 1544
22. Win K, Rodgers GM (2014) New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. doi:10.1002/ajh.23797
23. Schaefer JK, McBane RD, Black DF et al (2014) Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. doi:10.1160/TH14-03-0272
24. Larsen TB, Nielsen PB, Skjoth F et al (2014) Non-vitamin antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi-systematic review and meta-analysis of safety and efficacy outcomes. PLoS ONE 9:e114445
25. Vedovati MC, Germini F, Agnelli G, Becattini C (2014) Direct oral anticoagulants in patients with venous thromboembolism and cancer: a systematic review and meta-analysis. Chest. doi:10.1378/chest.14-0402
26. van der Hulle T, den Exter PL, Kooiman J et al (2014) Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 12:1116–1120
27. Sardar P, Chatterjee S, Herzog E et al (2015) New oral anticoagulants in patients with cancer: current state of evidence. Am J Ther 22:460–468
28. Lee AYY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153. doi:10.1056/NEJMoa025313
29. Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162(15):1729–1735
30. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R et al (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062–1072
31. Deitcher SR, Kessler CM, Merli G et al (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180 day period. Clin Appl Thromb Hemost 12:389–396
32. Lee A, Kamphuisen PW, Meyer G et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314(7):677–686. doi:10.0001/jama.2015.9243
33. Graham DJ, Reichman ME, Wernecke M et al (2015) Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 131(2):157–164
34. Sipahi I, Celik S, Tozun N (2014) A comparison of results of the us food and drug administration’s mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. JAMA Intern Med 174:150–151. doi:10.1001/jamainternmed.2013.12217
35. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systemic review and meta-analysis. Blood 124(15):2450–2458
36. Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease. Chest 141(2 Suppl):e419S–e494S. doi:10.1378/chest.11-2301
37. Erkens PM, Prins MH (2010) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 9:CD001100
38. Funk DM (2012) Coagulation assays and anticoagulant monitoring. Hematology 2012:460–465. doi:10.1182/asheducation-2012.1.460
39. Tripodi A (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032–4035. doi:10.1182/blood-2012-12-453076
40. Cuker A, Siegal DM, Crowther MA, Garcia DA (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64:1128–1139. doi:10.1016/j.jacc.2014.05.065
41. Douketis J (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: ACCP. Chest 141:e326S–e350S
42. Healey JS, Eikelboom J, Douketis J et al (2012) Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 126:343–348. doi:10.1161/CIRCULATIONAHA.111.090464
43. Sherwood MW, Douketis JD, Patel MR et al (2014) Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 129:1850–1859. doi:10.1161/CIRCULATIONAHA.113.005754
44. Garcia D, Alexander JH, Wallentin L et al (2014) Management and clinical outcomes in patients treated with apixaban versus warfarin undergoing procedures. Blood 124(25):3692–3698
45. Horlocker TT, Wedel DJ, Rowlingson JC et al (2010) Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (3rd Edition). Reg Anesth Pain Med 35(1):64–101 https://www.ismp.org/newsletters/acutecare/issue.aspx?id=82. Accessed 27 Nov 2014
46. Spyropoulos AC, Douketis JD (2012) How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120:2954–2962. doi:10.1182/blood-2012-06-415943
47. Baron TH, Kamath PS, McBane RD (2013) Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 368:2113–2124. doi:10.1056/NEJMra1206531
48. Wessler JD, Grip LT, Mendell J, Giugliano RP (2013) The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 61:2495–2502. doi:10.1016/j.jacc.2013.02.058
49. Gong IY, Kim RB (2013) Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 29:S24–33. doi:10.1016/j.cjca.2013.04.002
50. Feinberg J, Grabowitz L, Rotman-Pikielny P et al (2014) Dabigatran etexilate linked to fatal gastrointestinal hemorrhage. Isr Med Assoc 16(6):388–389
51. Lo JC-Y, Gerona RR (2014) A case of rivaroxaban associated intracranial hemorrhage. West J Emerg Med 15:375–377. doi:10.5811/westjem.2014.2.19440
52. Stöllberger C, Zuntner G, Bastovansky A, Finsterer J (2013) Cerebral hemorrhage under rivaroxaban. Int J Cardiol 167:e179–e181. doi:10.1016/j.ijcard.2013.03.185
53. Fountzilas C, George J, Levine R (2013) Dabigatran overdose secondary to acute kidney injury and amiodarone use. N Z Med J 126:110–112
54. Stöllberger C, Finsterer J (2014) Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state. Heart Lung 43:262–263. doi:10.1016/j.hrtlng.2014.03.004
55. Marcum ZA, Vande Griend JP, Linnebur SA (2012) FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 10:264–271. doi:10.1016/j.amjopharm.2012.05.002
56. Harper P, Young L, Merriman E (2012) Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366:864–866. doi:10.1056/NEJMc1112874
57. Schulman S, Beyth RJ, Kearon C et al (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: ACCP evidence-based clinical practice guidelines (8th edn). Chest 133:257S–298S
58. Hankey GJ, Eikelboom JW (2011) Dabigatran etexilate a new oral thrombin inhibitor. Circulation 123:1436–1450. doi:10.1161/CIRCULATIONAHA.110.004424
59. Liesenfeld K-H, Lehr T, Dansirikul C et al (2011) Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 9:2168–2175. doi:10.1111/j.1538-7836.2011.04498.x
60. Oldgren J, Budaj A, Granger CB et al (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32:2781–2789. doi:10.1093/eurheartj/ehr113
61. Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9–19. doi:10.1056/NEJMoa1112277
62. Alexander JH, Lopes RD, James S et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699–708. doi:10.1056/NEJMoa1105819
63. Davidson BL, Verheijen S, Lensing AA et al (2014) Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 174:947–953. doi:10.1001/jamainternmed.2014.946
64. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891. doi:10.1056/NEJMoa1009638
65. Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992. doi:10.1056/NEJMoa1107039
66. Abo-Salem E, Becker R (2014) Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians. J Thromb Thrombolysis 37:372–379. doi:10.1007/s11239-014-1060-y
67. Atay JK, Fanikos J, Barnes GD et al (2013) Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. Am J Cardiol 112:387–389. doi:10.1016/j.amjcard.2013.03.046
68. Pottegård A, Poulsen BK, Larsen MD, Hallas J (2014) Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study. J Thromb Haemost 12:1413–1418
69. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151. doi:10.1056/NEJMoa0905561
70. Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104. doi:10.1056/NEJMoa1310907
71. Majeed A, Hwang H-G, Connolly SJ et al (2013) Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128:2325–2332. doi:10.1161/CIRCULATIONAHA.113.002332
72. Piccini JP, Garg J, Patel MR et al (2014) Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 35:1873–1880. doi:10.1093/eurheartj/ehu083
73. Hylek E, Held C, Alexander JH et al (2014) Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial: predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 63:2141–2147
74. Research C for DE and drug safety and availability—FDA Drug Safety Communication: FDA study of medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. http://www.fda.gov/drugs/drugsafety/ucm396470.htm. Accessed 27 Nov 2014
75. Siegal DM, Cuker A (2014) Reversal of target-specific oral anticoagulants. Drug Discov Today. doi:10.1016/j.drudis.2014.05.013
76. Van Ryn J, Schurer J, Kink-Eiband M, Clemens A (2011) The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood 118(21):1004
77. Van Ryn J et al (2008) 13th congress of the European Hematology Association, Copenhagen, Denmark, June 12–15, 2008. Haematologica 93(s-1):148
78. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G et al (2012) Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemostas 10(9):1841–1848
79. Martin AC, LeBonniec B, Fischer AM (2013) Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. J Int Card 168(4):4228–4233. doi:10.1016/j.ijcard.2013.07.152
80. Perzborn E, Gruber A, Tinel H et al (2013) Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 110(1):162–172
81. Zahir H, Brown KS, Vandell AG et al (2015) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131:82–90
82. Godier A, Miclot A, LeBonniec B, Durand M, Fischer A-M, Emmerich J et al (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116(1):94–102
83. Marlu R, Hodaj E, Paris A et al (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomized crossover ex vivo study in healthy volunteers. Thromb Haemost 108:217–247
84. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 1214:1573–1579
85. Dager WE, Gosselin RC, Roberts AJ et al (2013) Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 41(5):42–46
86. Dentali F, Marchesi C, Pierfranceschi MG et al (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis. Thromb Haemost 106:429–438. doi:10.1160/TH11-01-0052
87. Levi M, Levy JH, Andersen HF, Truloff D (2010) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363:1791–1800. doi:10.1056/NEJMoa1006221
88. Siegal DM, Garcia DA, Crowther MA (2014) How I treat target-specific oral anticoagulant–associated bleeding. Blood 123:1152–1158. doi:10.1182/blood-2013-09-529784
89. Kaatz S, Kouides PA, Garcia DA et al (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87:S141–S145. doi:10.1002/ajh.23202
90. Kaatz S, Crowther M (2013) Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis 36:195–202. doi:10.1007/s11239-013-0923-y
91. van Ryn J et al (2014) American Heart Association Scientific Sessions 2014, Chicago, USA. http://www.abstractsonline.com/pp8/#!/3547/presentation/41579
92. Glund S (2013) 17765—A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Paper presented at the American Heart Association Scientific Sessions, Dallas, Texas, 16–20 November 2013
93. NCT02104947 clinicaltrials.gov
94. Hutchchaleelaha A et al (2012) European society of cardiology annual meeting. Munich, Germany 27
95. Lu G, DeGuzman FR, Hollenbach SJ et al (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19(4):446–451
96. Crowther M; ASH 2014 San Francisco abstract #4269 Session 332. antithrombotic therapy: poster III Monday, December 8
97. Crowther M, et al; ASH 2013. Abstract 3636, session 332. antithrombotic therapy: poster III Monday, December 9, 2013
98. Crowther M, et al. ISTH 2013 Amsterdam
99. A study in older subject to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of rivaroxaban—full text view—ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT02220725?term=NCT02220725&rank=1. Accessed 27 Nov 2014
100. A study in older subjects to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of apixaban—full text view—ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT02207725?term=NCT02207725&rank=1. Accessed 27 Nov 2014
101. Laulicht B, Bakhru S, Jiang X, et al (2013) Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at the 24th congress of the international society on thrombosis and haemostasis, Amsterdam, June 29–July 4, 2013. Abstract (http://www.eventure-online.com/enenture/publicAbstractView.do?id=2267118&congressId=6839)
102. Ansell JE, Bakhru S, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Eng J Med 371:2141–2142
103. Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for Dabigatran Reversal. N Engl J Med 373(6):511–520. doi:10.1056/NEJMoa1502000
104. Crowther MA, et al (2015) ISTH Congress 2015 abstract LB004
105. Burton R (2012) Improving care transitions. Robert Wood Johnson Foundation Health Policy Brief Sept 13, 2012. www.rwjf.org/content/dam/farm/reports/issue_briefs/2012/rwjf401314
106. Schillig J, Kaatz S, Hudson M et al (2011) Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med 6:322–328. doi:10.1002/jhm.910
107. Makowski CT, Jennings DL, Nemerovski CW et al (2013) The impact of pharmacist-directed patient education and anticoagulant care coordination on patient satisfaction. Ann Pharmacother 47:805–810. doi:10.1345/aph.1R686
108. Spyropoulos AC, Viscusi A, Singhal N et al (2014) Features of electronic health records necessary for the delivery of optimized anticoagulant therapy consensus of the EHR Task Force of the New York State Anticoagulation Coalition. Ann Pharmacother. doi:10.1177/1060028014555176
109. Cowell RPW (2014) Direct oral anticoagulants: integration into clinical practice. Postgrad Med J 90:529–539. doi:10.1136/postgradmedj-2013-132474
110. Michota F (2013) Transitions of care in anticoagulated patients. J Multidiscip Healthc 6:215–228. doi:10.2147/JMDH.S44068
111. Spyropoulos AC, Kardos J, Wigal P (2000) Outcome analyses of the outpatient treatment of venous thromboemolic disease using the low-molecular-weight heparin enoxaparin in a managed care organization. J Manag Care Pharm 6:298–304
112. Jiménez D, Aujesky D, Moores L et al (2010) Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 170:1383–1389. doi:10.1001/archinternmed.2010.199
113. Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625–651. doi:10.1093/europace/eut083
114. James, J (2013) patient engagement. In: Health affairs. http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=86. Accessed 27 Nov 2014
115. Hibbard JH, Greene J, Overton V (2013) Patients with lower activation associated with higher costs; delivery systems should know their patients’ “Scores”. Health Aff 32:216–222. doi:10.1377/hlthaff.2012.1064
116. Johnson A, Sandford J, Tyndall J (2003) Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003716
117. Institute for Safe Medication Practices (ISMP) (2003) https://www.ismp.org/Survey/surveyresults/NursingSurvey.asp. Accessed 27 Nov 2014
118. Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G et al (2013) Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 11(1):177–179
119. Bauer KA (2013) Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program 2013:464–470. doi:10.1182/asheducation-2013.1.464
120. Cushman M (2013) Treating acute venous thromboembolism—shift with Care. N Engl J Med 369(9):865–866
121. Thachil J (2014) The newer direct oral anticoagulants: a practical guide. Clin Med 14:165–175. doi:10.7861/clinmedicine.14-2-165
122. Weitz JI, Gross PL (2012) New oral anticoagulants: which one should my patient use? Hematology 2012:536–540. doi:10.1182/asheducation-2012.1.536
123. Schulman S (2014) New oral anticoagulant agents—general features and outcomes in subsets of patients. Thromb Haemost 111(4):575–582
124. Mahan CE, Spyropoulos AC, Fisher MD et al (2013) Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization. Clin Appl Thromb Hemost 19:504–512. doi:10.1177/1076029612470967
125. Decousus H, Tapson VF, Bergmann J-F et al (2011) Factors at admission associated with bleeding risk in medical patients: findings from the improve investigators. Chest 139:69–79. doi:10.1378/chest.09-3081
126. IPRO MAPP tool. http://qio.ipro.org/wp-content/uploads/2012/12/MAP2014_5_01.pdf
127. Kaatz S, Mahan CE (2014) Stroke prevention in patients with atrial fibrillation and renal dysfunction. Stroke 45:2497–2505. doi:10.1161/STROKEAHA.114.005117
128. Lippi G, Favaloro EJ, Mattiuzzi C (2014) Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring. Semin Thromb Hemost 40:756–765
129. Wang L, Zhang D, Raghavan N et al (2010) In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38:448–458
130. Härtter S, Koenen-Bergmann M, Sharma A et al (2012) Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 74:490–500. doi:10.1111/j.1365-2125.2012.04218.x
131. Kishimoto W, Ishiguro N, Ludwig-Schwellinger E et al (2014) In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold. Drug Metab Dispos 42:257–263. doi:10.1124/dmd.113.053769
132. Mendell J, Zahir H, Matsushima N et al (2013) Drug–drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13:331–342. doi:10.1007/s40256-013-0029-0
133. Delavenne X, Ollier E, Basset T et al (2013) A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 76(1):107–113. doi:10.1111/bcp.12055
134. Hansten PD, Horn JR (2012) The top 100 drug interactions: a guide to patient management, 2012th edn. Freeland, WA
135. FDA document: drug interactions and labeling > drug development and drug interactions: table of substrates, inhibitors, and inducers. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm
136. Risselada AJ, Visser MJ, van Roon EN (2013) Pulmonary embolism due to interaction between rivaroxaban and carbamazepine. Ned Tijdschr Geneeskd 157:A6568
137. Altena R, van Roon E, Folkeringa R et al (2014) Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring. Haematologica 99:e26–e27. doi:10.3324/haematol.2013.097287
138. Mueck W, Kubitza D, Becka M (2013) Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 76:455–466. doi:10.1111/bcp.12075
139. Gnoth MJ, Buetehorn U, Muenster U et al (2011) In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 338:372–380. doi:10.1124/jpet.111.180240